Figure 5: NCI8642 is able to compete with DKK1 in β-catenin translocation assay. (A) Panel a: Wnt3a-stimulated cells; panel b: cells treated with Wnt3a and DKK1; panel c: cells treated with Wnt3a, DKK1, and 50 μM NCI8642; panel d: cells treated with 50 μM NCI8642 only. (B) Concentration-response curve of NCI8642 (from 1 to 50 μM) expressed as % of activity. The activity was defined as the ratio of nuclear/cytoplasmic intensity normalized between Wnt3a + DMSO treatment (100% activity) and Wnt3a + DKK1 + DMSO treatment (0% activity).